Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 29 results.
User Information
Export Records
  1. 1.   Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
  2. Takebe, Naoko; Naqash, Abdul Rafeh; Coyne, Geraldine O'Sullivan; Kummar, Shivaani; Do, Khanh; Bruns, Ashley; Juwara,Lamin; Zlott, Jennifer; Rubinstein, Larry; Piekarz, Richard; Sharon, Elad; Streicher, Howard; Mittra, Arjun; Miller, Sarah B.; Ji,Jay; Wilsker,Deborah; Kinders,Robert; Parchment,Ralph; Chen,Li; Chang,Ting-Chia; Das,Biswajit; Mugundu, Ganesh; Doroshow, James H.; Chen, Alice P.
  3. CLINICAL CANCER RESEARCH. 2021, Apr 16; 27(14): 3834-3844.
  1. 2.   Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability
  2. Kharat,Suhas; Ding, Xia; Swaminathan, Divya; Suresh, Akshey; Singh, Manish; Sengodan,Satheesh; Burkett,Sandra; Marks, Hanna; Pamala, Chinmayi; He,Yafeng; Fox,Stephen; Buehler, Eugen C; Muegge,Kathrin; Martin, Scott E; Sharan,Shyam
  3. Science signaling. 2020, Aug 18; 13(645): pii: eaba8091.
  1. 3.   Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11and low-MGMT expression
  2. Rathkey, Daniel; Khanal, Manakamana; Murai, Junko; Zhang, Jingli; Sengupta, Manjistha; Jiang, Qun; Morrow, Betsy; Evans,Christine; Chari,Raj; Fetsch, Patricia; Chung, Hye-Jung; Xi, Liqiang; Roth, Mark; Filie, Armando; Raffeld, Mark; Thomas, Anish; Pommier, Yves; Hassan, Raffit
  3. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020, Jan 28; pii: S1556-0864(20)30035-6.
  1. 4.   Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay
  2. Ji, Jay; Zhang, Yiping; Redon, Christophe E.; Reinhold, William C.; Chen, Alice P.; Fogli, Laura K.; Holbeck, Susan L.; Parchment, Ralph; Hollingshead, Melinda; Tomaszewski, Joseph E.; Dudon, Quentin; Pommier, Yves; Doroshow, James H.; Bonner, William M.
  3. PLOS ONE. 2017, Feb 3; 12(2): e0171582.
  1. 5.   Pharmacodynamic analyses in a multi-laboratory network: lessons from the poly(ADP-ribose) assay
  2. Ferry-Galow, K. V.; Ji, J.; Kinders, R. J.; Zhang, Y.; Czambel, R. K.; Schmitz, J. C.; Herzog, J.; Evrard, Y. A.; Parchment, R. E.
  3. Seminars in Oncology. 2016, Aug; 43(4): 492-500.
  1. 6.   Advances in using PARP inhibitors to treat cancer
  2. Kummar, S.; Chen, A.; Parchment, R. E.; Kinders, R. J.; Ji, J.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Bmc Medicine. 2012, Mar; 10
  1. 7.   A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
  2. Kummar, S.; Ji, J. P.; Morgan, R.; Lenz, H. J.; Puhalla, S. L.; Belani, C. P.; Gandara, D. R.; Allen, D.; Kiesel, B.; Beumer, J. H.; Newman, E. M.; Rubinstein, L.; Chen, A.; Zhang, Y. P.; Wang, L. H.; Kinders, R. J.; Parchment, R. E.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Clinical Cancer Research. 2012, Mar; 18(6): 1726-1734.
  1. 8.   Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
  2. Ji, J. P.; Kinders, R. J.; Zhang, Y. P.; Rubinstein, L.; Kummar, S.; Parchment, R. E.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Plos One. 2011, Oct; 6(10): 8.
  1. 9.   Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
  2. Kummar, S.; Chen, A.; Ji, J. P.; Zhang, Y. P.; Reid, J. M.; Ames, M.; Jia, L.; Weil, M.; Speranza, G.; Murgo, A. J.; Kinders, R.; Wang, L. H.; Parchment, R. E.; Carter, J.; Stotler, H.; Rubinstein, L.; Hollingshead, M.; Melillo, G.; Pommier, Y.; Bonner, W.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Cancer Research. 2011, Sep; 71(17): 5626-5634.
  1. 10.   Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress
  2. Aggarwal, M.; Sommers, J. A.; Shoemaker, R. H.; Brosh, R. M.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2011, Jan; 108(4): 1525-1530.
  1. 11.   Development of a Validated Immunofluorescence Assay for gamma H2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity
  2. Kinders, R. J.; Hollingshead, M.; Lawrence, S.; Ji, J. P.; Tabb, B.; Bonner, W. M.; Pommier, Y.; Rubinstein, L.; Evrard, Y. A.; Parchment, R. E.; Tomaszewski, J.; Doroshow, J. H.; Natl Canc Inst Phase 0 Clinical, T.
  3. Clinical Cancer Research. 2010, Nov; 16(22): 5447-5457.
  1. 12.   Histone yH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
  2. Redon, C. E.; Nakamura, A. J.; Zhang, Y. W.; Ji, J. P.; Bonner, W. M.; Kinders, R. J.; Parchment, R. E.; Doroshow, J. H.; Pommier, Y.
  3. Clinical Cancer Research. 2010, Sep; 16(18): 4532-4542.
  1. 13.   4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesufonate) (NSC 88915) and Related Novel Steroid Derivatives as Tyrosyl-DNA Phosphodiesterase (Tdp1) Inhibitors
  2. Dexheimer, T. S.; Gediya, L. K.; Stephen, A. G.; Weidlich, I.; Antony, S.; March, C.; Interthal, H.; Nicklaus, M.; Fisher, R. J.; Njar, V. C.; Pommier, Y.
  3. Journal of Medicinal Chemistry. 2009 52(22): 7122-7131.
  1. 14.   Response: Re: Antitumor Efficacy Testing in Rodents
  2. Hollingshead, M. G.
  3. Journal of the National Cancer Institute. 2009 101(22): 1593-1594.
  1. 15.   Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
  2. Kummar, S.; Kinders, R.; Gutierrez, M. E.; Rubinstein, L.; Parchment, R. E.; Phillips, L. R.; Ji, J. P.; Monks, A.; Low, J. A.; Chen, A.; Murgo, A. J.; Collins, J.; Steinberg, S. M.; Eliopoulos, H.; Giranda, V. L.; Gordon, G.; Helman, L.; Wiltrout, R.
  3. Journal of Clinical Oncology. 2009 27(16): 2705-2711.
  1. 16.   Liquid Chromatographic Determination of NSC 737664 (ABT-888: An Inhibitor of Poly(ADP-ribose) Polymerase (PARP)) in Plasma and Urine in a Phase 0 Clinical Trial
  2. Phillips, L. R.; Hill, K. D.; Majerova, E.
  3. Journal of Liquid Chromatography & Related Technologies. 2009 32(2): 261-272.
  1. 17.   In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016
  2. Russo, A. L.; Kwon, H. C.; Burgan, W. E.; Carter, D.; Beam, K.; Weizheng, X.; Zhang, J.; Slusher, B. S.; Chakravarti, A.; Tofilon, P. J.; Camphausen, K.
  3. Clinical Cancer Research. 2009 15(2): 607-612.
  1. 18.   Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts
  2. Kinders, R. J.; Hollingshead, M.; Khin, S.; Rubinstein, L.; Tomaszewski, J. E.; Doroshow, J. H.; Parchment, R. E.
  3. Clinical Cancer Research. 2008 14(21): 6877-6885.
  1. 19.   Degradation of BRCA2 in Alkyltransferase-Mediated DNA Repair and Its Clinical Implications
  2. Philip, S.; Swaminathan, S.; Kuznetsov, S. G.; Kanugula, S.; Biswas, K.; Chang, S.; Loktionova, N. A.; Haines, D. C.; Kaldis, P.; Pegg, A. E.; Sharant, S. K.
  3. Cancer Research. 2008 68(23): 9973-9981.
  1. 20.   Generation and characterization of telomere length maintenance in tankyrase 2-deficient mice
  2. Chiang, Y. J.; Nguyen, M. L.; Gurunathan, S.; Kaminker, P.; Tessarollo, L.; Campisi, J.; Hodes, R. J.
  3. Molecular and Cellular Biology. 2006, MAR; 26(6): 2037-2043.
  1. 21.   Inhibition of melanoma growth and metastasis by ATF2-derived peptides
  2. Bhoumik, A.; Gangi, L.; Ronai, Z.
  3. Cancer Research. 2004, NOV 15; 64(22): 8222-8230.
  1. 22.   Substrate binding and catalysis of Ecto-ADP-ribosyltransferase 2.2 from rat
  2. Ritter, H.; Koch-Nolte, F.; Marquez, V. E.; Schulz, G. E.
  3. Biochemistry. 2003 42(34): 10155-10162.
  1. 23.   Cell-free systems to study apoptosis
  2. Fearnhead, H. O.
  3. Methods in cell biology. 2001; 66 : 167-185.
  1. 24.   Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: Evidence for cytotoxic mechanisms different from inhibition of protein synthesis
  2. Iordanov, M. S.; Ryabinina, O. P.; Wong, J.; Dinh, T. H.; Newton, D. L.; Rybak, S. M.; Magun, B. E.
  3. Cancer Research. 2000 60(7): 1983-1994.
  1. 25.   DNA reactions, mutagenic action and stealth properties of polycyclic aromatic hydrocarbon carcinogens (Review)
  2. Dipple, A.; Khan, Q. A.; Page, J. E.; Ponten, I.; Szeliga, J.
  3. International Journal of Oncology. 1999 14(1): 103-111.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel